People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| OncoResponse Inc | — | Biotechnology | Series C | $109.0M | $39.3M | 2015 |
| Petra Pharma Corp | — | Biotechnology | Series B | $58.8M | $1.1B | 2015 |
| VBI Vaccines Inc/BC | — | Pharmaceuticals | Series A | $41.6M | $145.6M | 2018 |
| Skylark Bio, Inc. | — | Biotechnology | Series C | $40.9M | $751.0M | 2022 |
| Basking Biosciences, Inc. | — | Biotechnology | Series B | $29.4M | $261.0M | 2023 |
| Magnolia Neurosciences Corp | — | Biotechnology | Series B | $26.4M | $724.5M | 2018 |
| Lodo Therapeutics Corp | — | Biotechnology | Series B | $19.9M | $788.5M | 2015 |
| Variation Biotechnologies (US), Inc. | — | Biotechnology | Series A | $17.1M | $54.2M | 2011 |
| Rodeo Therapeutics Corp | — | Biotechnology | Series A | $14.3M | $323.6M | 2017 |
| Ally Therapeutics, Inc. | — | Pharmaceuticals | Series A | $10.0M | $309.7M | 2019 |
| ApoGen Biotechnologies, Inc. | — | Biotechnology | Series A | $7.6M | $273.5M | 2016 |
| Oncofactor Corp | — | Biotechnology | Seed | $3.1M | $44.4M | 2011 |
| XORI Corp | — | Biotechnology | Seed | $2.1M | $93.4M | 2009 |
Steve Gillis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steve Gillis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.